Quick answer: Mounjaro, Ozempic, Wegovy, and Zepbound are four brand-name injectable medications built on just two molecules. Ozempic and Wegovy are the same drug, semaglutide, sold under different labels (Ozempic for type 2 diabetes, Wegovy for weight loss). Mounjaro and Zepbound are the same drug, tirzepatide, split the same way (Mounjaro for diabetes, Zepbound for weight loss). Tirzepatide (Mounjaro and Zepbound) has produced the largest average weight loss in trials, roughly 20 to 22 percent of body weight, while semaglutide (Ozempic and Wegovy) lands closer to 15 percent. If your goal is weight loss and you can get it covered, Zepbound is usually the strongest pick. If you have type 2 diabetes, the choice is Mounjaro or Ozempic.
This is the single most confusing corner of the weight-loss drug world, and the confusion is by design. The pharmaceutical labeling makes four products look like four different choices when there are really only two active ingredients. Once you understand that Ozempic and Wegovy are twins and Mounjaro and Zepbound are twins, every question about cost, coverage, dosing, and results gets a lot simpler. Below is the full breakdown: a side-by-side table, every meaningful matchup explained as a plain question, the insider reason insurance covers one twin and not the other, real 2026 cost ranges, and a deep FAQ.
Mounjaro vs Ozempic vs Wegovy vs Zepbound: the full comparison table
Start here. This single table answers most of what people come looking for, and it makes the two-molecule structure obvious at a glance. Read it across the rows and you will see Ozempic and Wegovy share a generic name, and Mounjaro and Zepbound share a generic name.
| Mounjaro | Ozempic | Wegovy | Zepbound | |
|---|---|---|---|---|
| Brand name | Mounjaro | Ozempic | Wegovy | Zepbound |
| Generic (active drug) | Tirzepatide | Semaglutide | Semaglutide | Tirzepatide |
| Maker | Eli Lilly | Novo Nordisk | Novo Nordisk | Eli Lilly |
| Drug class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| FDA-approved use | Type 2 diabetes | Type 2 diabetes | Chronic weight management; also cardiovascular risk reduction | Chronic weight management; also obstructive sleep apnea |
| Minimum age | 18 | 18 | 12 | 18 |
| Dosing cadence | Once weekly injection | Once weekly injection | Once weekly injection | Once weekly injection |
| Average weight loss in trials | About 15 to 21 percent (diabetes and obesity studies) | About 6 to 8 percent (diabetes dosing) | About 15 percent | About 18 to 22 percent |
| Rough monthly cash cost (2026) | About $1,000 to $1,100 list; $400 to $550 via direct vial program | About $950 to $1,050 list | About $1,300 list; $500 via direct cash program | About $1,000 to $1,300 list; $350 to $650 via direct vial program |
Two things in that table surprise almost everyone. First, the weight loss numbers for Ozempic look low compared to Wegovy even though they are the same molecule. That is not a typo. It is a dose difference, explained below. Second, the cash prices are all north of $900 at list, but the real prices people pay through manufacturer direct-cash programs are roughly half that. The list price is rarely what anyone actually pays.
Ozempic vs Wegovy: what’s the difference?
Ozempic and Wegovy are the exact same drug, semaglutide, made by the same company, Novo Nordisk. The difference is the FDA label and the maximum dose. Ozempic is approved to treat type 2 diabetes and tops out at 2.0 mg per week. Wegovy is approved for chronic weight management and goes up to 2.4 mg per week. Same molecule, same weekly injection, different box and different ceiling.
That small dose gap explains the weight loss numbers that confuse people. In its diabetes trials at diabetes doses, semaglutide as Ozempic produced average weight loss around 6 to 8 percent of body weight, which is a side benefit, not the goal. As Wegovy, pushed to the higher 2.4 mg obesity dose and studied specifically for weight, the same drug produced average loss around 15 percent in the STEP program. The drug did not change. The dose and the trial design did. This is also why doctors sometimes prescribe Ozempic off label for weight loss and titrate it up: it is the same compound a step below the weight-loss ceiling.
Dosing
Both start low and step up to limit nausea. Semaglutide typically begins at 0.25 mg per week for four weeks, then climbs every four weeks. Ozempic’s path ends at 0.5, 1.0, or 2.0 mg. Wegovy’s path adds the 1.7 mg and 2.4 mg steps. The slow titration is not optional padding; it is how you avoid the worst of the gut side effects.
Side effects
Identical, because it is the same drug: nausea, diarrhea, constipation, vomiting, and burping are the common ones, usually worst right after a dose increase and fading as your body adjusts. The serious but rare warnings include pancreatitis, gallbladder problems, and a boxed warning about thyroid C-cell tumors seen in rodents, which is why anyone with a personal or family history of medullary thyroid cancer or MEN 2 should not take it.
Weight loss data
Wegovy wins on paper only because it is dosed for weight. At matched doses they would behave the same. For a head-to-head on how semaglutide stacks up against the tirzepatide twins, see our breakdown of semaglutide vs tirzepatide.
Cost
Wegovy generally carries a higher list price than Ozempic, around $1,300 versus roughly $1,000 a month, though Novo Nordisk’s direct cash program has brought self-pay Wegovy down toward $500 for people paying out of pocket. Insurance, ironically, often covers Ozempic more readily than Wegovy, which is the central paradox of this whole category and the reason so many people end up on the diabetes twin for a weight goal.
Mounjaro vs Zepbound: what’s the difference?
Mounjaro and Zepbound are the exact same drug, tirzepatide, made by the same company, Eli Lilly. As with the semaglutide twins, the only differences are the FDA-approved use and the marketing. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and, more recently, for moderate to severe obstructive sleep apnea in adults with obesity. Same molecule, same once-weekly shot, same dose ladder (2.5, 5, 7.5, 10, 12.5, and 15 mg), different label.
Here the twin story is even cleaner than semaglutide’s, because the dose range is identical between Mounjaro and Zepbound. A person on 15 mg of Mounjaro and a person on 15 mg of Zepbound are taking precisely the same thing in the same amount. The pen and the box differ. The drug does not. This is worth knowing because if one is covered by your plan and the other is not, your prescriber can sometimes work with that.
Dosing
Both start at 2.5 mg weekly for four weeks (a starter dose that is not meant to be therapeutic, just a way to ease your gut in), then step up by 2.5 mg every four weeks as tolerated, up to a maximum of 15 mg. Most people land somewhere between 5 and 15 mg depending on response and side effects.
Side effects
The same profile as the semaglutide twins, since both classes act on the GLP-1 system: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, mostly around dose increases. Tirzepatide carries the same boxed thyroid C-cell tumor warning and the same cautions around pancreatitis and gallbladder disease. Because tirzepatide also hits the GIP receptor, some people report that nausea is a touch more manageable relative to the appetite suppression they get, though that is individual and not a guarantee.
Weight loss data
This is where tirzepatide separates from the pack. In the SURMOUNT obesity trials, Zepbound at the top dose produced average weight loss in the 20 to 22 percent range, the highest of any of these four drugs. For the deeper numbers, see tirzepatide weight loss results.
Cost
List prices for both run roughly $1,000 to $1,300 a month. The game changer is Lilly’s direct vial program, which has offered self-pay tirzepatide (sold under the Zepbound name for weight) at lower price points, with the smallest starter vials in the $350 to $500 range and higher doses around $500 to $650 for people paying cash. That single channel has done more to make tirzepatide accessible than any insurance change.
Ozempic vs Mounjaro: which works better for weight loss?
Head to head for weight loss, tirzepatide (Mounjaro) generally beats semaglutide (Ozempic). The one large trial that compared them directly for weight, SURMOUNT-5, pitted Zepbound (tirzepatide) against Wegovy (semaglutide), the two weight-approved twins, and tirzepatide produced clearly greater average weight loss, roughly 20 percent versus about 14 percent over the study. Since Ozempic and Mounjaro are the diabetes twins of those same molecules, the same ranking holds: tirzepatide tends to take off more weight than semaglutide.
The likely reason is mechanism. Semaglutide is a single agonist, hitting only the GLP-1 receptor. Tirzepatide is a dual agonist, hitting both GLP-1 and GIP, a second gut hormone receptor. Two levers appear to be better than one for appetite and metabolic effect. That said, both are diabetes drugs first, so for a person whose actual goal is weight loss, the cleaner question is usually Wegovy vs Zepbound, the two drugs actually approved and dosed for it. Using the diabetes twins off label for weight is common but means navigating the weaker coverage logic discussed below.
If you are weighing newer options on the horizon, it is worth understanding how these compare to the next generation. Retatrutide, a triple agonist still in trials, has posted even higher numbers, which we cover in retatrutide vs tirzepatide and what retatrutide is.
Wegovy vs Zepbound: head to head
For pure weight loss, this is the matchup that matters, because Wegovy and Zepbound are the two drugs the FDA actually approved for chronic weight management. Zepbound (tirzepatide) wins on average weight loss. In SURMOUNT-5, the only major direct comparison, Zepbound delivered roughly 20 percent average loss against Wegovy’s roughly 14 percent. That is a meaningful gap, not a rounding difference.
| Factor | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| Class | GLP-1 single agonist | GIP and GLP-1 dual agonist |
| Average weight loss | About 15 percent (SURMOUNT-5: about 14 percent) | About 20 to 22 percent |
| Minimum age | 12 and up (approved for adolescents) | 18 and up |
| Extra approvals | Cardiovascular risk reduction in adults with heart disease | Obstructive sleep apnea in adults with obesity |
| Direct cash price | About $500 per month self-pay | About $350 to $650 per month self-pay by dose |
| Maker | Novo Nordisk | Eli Lilly |
The decision is not always just the bigger number. Wegovy has a dedicated approval for reducing the risk of heart attack and stroke in adults with established cardiovascular disease, which can tip the choice for someone with heart disease. Wegovy is also approved down to age 12, while Zepbound is adults only. Zepbound, on its side, now carries an approval for obstructive sleep apnea, which can change insurance coverage for someone with that diagnosis. So the honest answer is: Zepbound for maximum weight loss, but Wegovy if a cardiovascular indication or an adolescent patient is in the picture.
The insider detail: why insurance covers the diabetes twin but not the weight-loss twin
Here is the thing that frustrates people more than anything else in this category, and almost no one explains it up front. Within each pair, the molecule is identical, but insurance treats the two labels completely differently. Many US health plans cover the diabetes versions, Ozempic and Mounjaro, because treating type 2 diabetes is a long-accepted, reimbursed medical need. The same plans frequently exclude the weight-loss versions, Wegovy and Zepbound, even though they are the same chemicals, because obesity drug coverage has historically been carved out as a non-covered or optional benefit.
The result is a strange ground reality. A person who wants to lose weight may find their plan flatly denies Wegovy and Zepbound but readily covers Ozempic and Mounjaro. That is why off-label prescribing of the diabetes twins for weight loss became so widespread: it was often the only path to an affordable, covered version of the drug. It is the same active ingredient, at the same or a nearby dose, in a box with a different name and a different price.
This is also why the manufacturers built direct cash programs. Novo Nordisk sells self-pay Wegovy, and Eli Lilly sells self-pay tirzepatide vials, specifically to reach the millions of people whose insurance will not touch the weight-loss label. If your plan denies the weight version, your two realistic moves are: ask your prescriber whether the diabetes twin is appropriate and covered for you, or use the maker’s direct cash channel for the weight version. Knowing the twins are chemically identical is what makes that conversation possible.
What do these drugs cost, and how do savings cards and compounded versions fit in?
The list prices on all four sit roughly between $950 and $1,300 a month, but the list price is theater. Almost no one pays it. What you actually pay depends on three channels: insurance, manufacturer savings cards, and direct cash programs.
| Payment route | What you pay | Who it fits |
|---|---|---|
| Insurance covered (with a copay card) | As low as $0 to $25 a month for commercially insured, when the drug is on formulary | People whose plan covers their specific drug and label |
| Manufacturer savings card, partial coverage | Often around $550 a month if your plan covers it but at a high tier | Commercially insured with weak coverage |
| Direct cash vial program | About $350 to $650 a month depending on drug and dose | Uninsured or plans that exclude the drug |
| Full list price, no help | About $950 to $1,300 a month | Almost no one should pay this |
Two cautions worth saying plainly. First, manufacturer copay savings cards usually apply only to people with commercial insurance and are not available to anyone on Medicare, Medicaid, or other government plans by law. If you are on Medicare, the savings card is off the table, and your real options are formulary coverage or the cash vial program.
Second, the compounded versions. During the 2023 to 2024 shortages, compounding pharmacies legally sold cheaper compounded semaglutide and tirzepatide. Once the FDA declared the shortages resolved, that window largely closed, and mass compounding of these drugs is no longer permitted in the way it was. Compounded products are not FDA-approved, dosing and purity can vary, and some online sellers ship versions that are not the same salt form studied in trials. If a website offers tirzepatide or semaglutide at a suspiciously low price with no prescriber involvement, treat it as a red flag. The legitimate cheap route in 2026 is the manufacturers’ own direct cash vials, not a no-questions-asked compounding site.
Which one should you actually ask your doctor about?
Match the drug to your real goal and your coverage. The two-molecule structure makes this simpler than four product names suggest. Here is the decision guidance by what you are actually trying to do.
| Your situation | Reasonable first ask | Why |
|---|---|---|
| Type 2 diabetes, want best glucose and weight benefit | Mounjaro | Tirzepatide tends to lower A1C and weight more than semaglutide |
| Type 2 diabetes, plan covers Ozempic only | Ozempic | Strong, established diabetes drug your plan will likely pay for |
| Weight loss is the goal, want the biggest result | Zepbound | Highest average weight loss in trials of these four |
| Weight loss plus established heart disease | Wegovy | Carries an FDA approval for cardiovascular risk reduction |
| Weight loss plus obstructive sleep apnea | Zepbound | Carries an FDA approval for moderate to severe OSA with obesity |
| Adolescent (12 to 17) needing weight management | Wegovy | The only one of the four approved down to age 12 |
| Uninsured, paying cash, want lowest price | Direct cash vials (Zepbound or Wegovy program) | Roughly half the list price without insurance games |
One honest caveat on all of this: the strongest drug on paper is not always the right drug for you. Side effect tolerance, kidney and gallbladder history, thyroid history, pregnancy plans, and what your plan will actually pay for all shape the real answer. Bring this table to a clinician and let them read it against your full history rather than picking a name off an ad. If you are getting bloodwork to track how a GLP-1 is affecting your metabolic markers, it is often smarter to capture a full baseline at once. Here is how a full-body panel compares so you can see where your A1C, lipids, and liver markers stand before and during treatment.
How do the side effects compare across all four?
Because all four act on the GLP-1 system, the side effect profiles are more alike than different. The common complaints are gastrointestinal: nausea, diarrhea, constipation, vomiting, and burping. These cluster around the first weeks and around each dose increase, then usually settle. The slow titration schedule every four weeks exists precisely to keep these tolerable.
- Most common: nausea, diarrhea, constipation, stomach pain, vomiting, fatigue. Worst early, eases over time for most people.
- Less common but important: gallbladder problems (including gallstones), dehydration from vomiting or diarrhea, and injection-site reactions.
- Rare and serious: pancreatitis, kidney injury usually tied to severe dehydration, and a boxed warning for thyroid C-cell tumors based on rodent studies. People with a history of medullary thyroid cancer or MEN 2 syndrome should not use any of these.
A practical insider note: the GLP-1 drugs slow stomach emptying, which is part of how they curb appetite, and that same effect is why anesthesiologists now ask whether you are on one before surgery, since a fuller stomach raises aspiration risk. If you have a procedure with sedation coming up, tell the team you are on Mounjaro, Ozempic, Wegovy, or Zepbound. This is the kind of detail patients rarely think to mention and clinicians increasingly need to know. As always, talk to a clinician about your own history before starting or stopping any of these.
FAQ
Are Ozempic and Wegovy the same drug?
Yes. Both are semaglutide made by Novo Nordisk. Ozempic is the label approved for type 2 diabetes (up to 2.0 mg weekly), and Wegovy is the label approved for weight management (up to 2.4 mg weekly). The molecule is identical; the dose ceiling and the FDA-approved use differ, which is why their trial weight-loss numbers look different.
Are Mounjaro and Zepbound the same drug?
Yes. Both are tirzepatide made by Eli Lilly, with the exact same dose ladder from 2.5 mg up to 15 mg weekly. Mounjaro is the diabetes label, and Zepbound is the weight management and sleep apnea label. A given dose of one is chemically identical to the same dose of the other.
Which is best for weight loss, Ozempic, Wegovy, Mounjaro, or Zepbound?
For maximum average weight loss, Zepbound (tirzepatide) leads, at roughly 20 to 22 percent in trials, followed by Wegovy (semaglutide) at about 15 percent. The diabetes twins, Ozempic and Mounjaro, are the same molecules but dosed and studied for blood sugar, so their on-label weight numbers look smaller. The one direct comparison trial, SURMOUNT-5, favored Zepbound over Wegovy.
Why does insurance cover Ozempic but not Wegovy if they are the same drug?
Because insurers reimburse based on the FDA-approved use, not the molecule. Treating type 2 diabetes (Ozempic) is a long-covered medical need, while obesity drug coverage (Wegovy) has historically been excluded or made optional by many plans. Same chemical, different label, different coverage logic. That gap is exactly why off-label use of the diabetes versions for weight loss became common.
What is the difference between a GLP-1 and a dual GIP/GLP-1 drug?
Semaglutide (Ozempic, Wegovy) is a single GLP-1 receptor agonist, mimicking one gut hormone that curbs appetite and improves blood sugar. Tirzepatide (Mounjaro, Zepbound) is a dual agonist that activates both the GLP-1 and the GIP receptors, a second gut hormone pathway. The dual action appears to drive somewhat greater weight loss, which is the leading theory for why tirzepatide outperforms semaglutide in trials.
How much do these cost without insurance in 2026?
List prices run roughly $950 to $1,300 a month, but manufacturer direct cash programs have pushed real self-pay prices to about $350 to $650 a month for tirzepatide vials and around $500 a month for self-pay Wegovy, depending on dose. Manufacturer copay savings cards can drop the cost to near zero for commercially insured patients, but they are not available to people on Medicare or Medicaid.
Can I switch between these drugs?
Switching is common and is done under a prescriber’s guidance, usually restarting the titration ladder rather than matching doses one to one. People switch for cost, coverage changes, side effect tolerance, or to chase a better result, for example moving from semaglutide to tirzepatide for more weight loss. Do not switch on your own; the starting doses and titration differ, and your clinician will set the plan.
Are compounded semaglutide and tirzepatide a safe way to save money?
They are riskier than the brand versions. Compounded GLP-1 drugs are not FDA-approved, and after the official shortages ended, large-scale compounding of these molecules is no longer broadly permitted. Purity, dose accuracy, and even the chemical salt form can vary between sellers. The safer low-cost route in 2026 is the manufacturers’ own direct cash vial programs, which sell the real, approved drug at roughly half the list price.
Do you keep the weight off after stopping these drugs?
Often not fully. Studies show that when people stop semaglutide or tirzepatide, a meaningful portion of the lost weight tends to return over the following year, because the drugs work by ongoing appetite and metabolic effects that fade once they leave your system. That is why clinicians increasingly frame these as long-term treatments for a chronic condition rather than a short course. Plan the cost and the strategy around staying on it, not a quick fix.
Which is stronger for type 2 diabetes, Mounjaro or Ozempic?
In head-to-head diabetes trials, tirzepatide (Mounjaro) generally lowered A1C and body weight more than semaglutide (Ozempic). Both are excellent diabetes drugs and both reduce blood sugar well, so the choice often comes down to what your plan covers, how you tolerate each, and your prescriber’s read on your case. Talk to a clinician about which fits your numbers and history.
